Abstract
The increased cardiovascular risk has been implicated in both HIV infection and antirretroviral therapy. The endothelial dysfunction triggered by the infection and the metabolic abnormalities associated with therapy predispose to premature atherosclerosis. The recognition of the increased cardiovascular risk in these patients will allow more appropriate prevention strategies, as well as therapy optimization with lipid-lowering agents and antirretroviral therapy modification.
MeSH terms
-
Antiretroviral Therapy, Highly Active / adverse effects
-
Cardiovascular Diseases / drug therapy
-
Cardiovascular Diseases / epidemiology*
-
Cardiovascular Diseases / etiology*
-
Cardiovascular Diseases / prevention & control
-
Dyslipidemias / chemically induced
-
Endothelium, Vascular / physiopathology
-
HIV Infections / complications*
-
HIV Infections / physiopathology
-
HIV-Associated Lipodystrophy Syndrome / etiology
-
Humans
-
Hypolipidemic Agents / therapeutic use
-
Metabolic Syndrome / chemically induced
-
Risk Factors